Skip to main content
Adaptive Biotechnologies enters Dx partnership with Janssen
6/22/2017

Adaptive Biotechnologies and Johnson & Johnson subsidiary Janssen have agreed on a collaboration to assess the effectiveness of Janssen's Darzalex for multiple myeloma through minimal residual disease measurement using Adaptive's NGS-based ClonoSeq assay. Janssen will provide Adaptive development with funding and potential future milestone payments, as well as an upfront technology access payment of an undisclosed amount.

Full Story: